Wednesday, July 8, 2020

Tackling COVID-19 at a Potential Achilles Heel, siRNA: A Conversation with Alnylam’s CEO John Maraganore

Having recent success in lung delivery, short interfering RNA (siRNA) is poised to be a powerful new modality to treat COVID-19. Alnylam and Vir Biotechnology expanded their 2017 partnership earlier this month – leveraging Alnylam’s lung delivery technology of novel conjugates of...

Harvard’s Francisco Quintana Explores the Impact of Environmental Factors on the Pathogenesis of Multiple Sclerosis

Multiple sclerosis, an autoimmune disorder, is one of the more prevalent rare diseases worldwide. An estimated 2.3 million people are living with multiple sclerosis, whose cause remains unknown. Francisco J. Quintana, Ph.D., professor of neurology at Harvard Medical School and the Ann Romney...

Apitope’s Research Seeks to Put Cause of Multiple Sclerosis into Remission

The National Organization of Rare Diseases (NORD) describes multiple sclerosis (MS) as a chronic neuroimmunologic disorder involving the brain, spinal cord and optic nerves. MS is just one of 7000 known diseases categorized as a “rare disease,” but in addition to its...

Amicus Therapeutics: A Patient-First Approach to Treating Rare Diseases

Rare diseases have long posed a dual challenge. First, since there are relatively few patients by definition, they are not the highest priority for most drug makers. Second, many of them have proven quite difficult to effectively treat, let alone cure. The passage of the...

TDI Serves as a Bridge Between Academia and Industry, Leveraging All It Needs for Innovation

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) and WuXi AppTec Content Team The translation of academic discoveries into therapeutic products remains an issue despite passage of the Bayh-Dole Act (or Patent and Trademark Law Amendments...

SUBSCRIBE TO OUR NEWSLETTER

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WuXi NEWS